Potentially highly potent drugs for 2019-nCoV

Duc Duy Nguyen, Kaifu Gao, Jiahui Chen, Rui Wang, Guo-Wei Wei

Research output: Working paperPreprint


The World Health Organization (WHO) has declared 2019 novel coronavirus (2019-nCoV) infection outbreak a global health emergency. Currently, there is no effective anti-2019-nCoV medication. The sequence identity of the 3CL proteases of 2019-nCoV and SARS is 96%, which provides a sound foundation for structural-based drug repositioning (SBDR). Based on a SARS 3CL protease X-ray crystal structure, we construct a 3D homology structure of 2019-nCoV 3CL protease. Based on this structure and existing experimental datasets for SARS 3CL protease inhibitors, we develop an SBDR model using deep learning and mathematics to screen 1465 drugs in the DrugBank that have been approved by the U.S. Food and Drug Administration (FDA). We found that a number of FDA approved drugs are potentially highly potent to 2019-nCoV.
Original languageEnglish
StatePublished - Feb 13 2020

Bibliographical note

Authors retain copyright and choose from several distribution/reuse options under which to make the article available (CC BY, CC BY-NC, CC BY-ND, CC BY-NC-ND, CC0, or no reuse).


  • bioinformatics


Dive into the research topics of 'Potentially highly potent drugs for 2019-nCoV'. Together they form a unique fingerprint.

Cite this